# Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

> **NCT00077961** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 49 (—)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** CAMPATH (alemtuzumab)

## Key facts

- **NCT ID:** NCT00077961
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-12
- **Primary completion:** 2006-02
- **Final completion:** —
- **Target enrollment:** 49 (—)
- **Last updated:** 2015-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077961, "Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00077961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*